44 results on '"Raschi A"'
Search Results
2. Adopting STOPP/START Criteria Version 3 in Clinical Practice: A Q&A Guide for Healthcare Professionals
3. Antipsychotic-Related DRESS Syndrome: Analysis of Individual Case Safety Reports of the WHO Pharmacovigilance Database
4. Peer Review in Pharmacovigilance: Lens on Disproportionality Analysis
5. The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Explanation and Elaboration
6. The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Development and Statement
7. Emerging Toxicities of Antibody-Drug Conjugates for Breast Cancer: Clinical Prioritization of Adverse Events from the FDA Adverse Event Reporting System
8. Enhancing Transparency in Defining Studied Drugs: The Open-Source Living DiAna Dictionary for Standardizing Drug Names in the FAERS
9. Tumor Lysis Syndrome with CD20 Monoclonal Antibodies for Chronic Lymphocytic Leukemia: Signals from the FDA Adverse Event Reporting System
10. Challenges and Opportunities in Accessing and Analysing FAERS Data: A Call Towards a Collaborative Approach
11. Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians
12. Deliberate Self-Poisoning: Real-Time Characterization of Suicidal Habits and Toxidromes in the Food and Drug Administration Adverse Event Reporting System
13. Erice Manifesto 2022: On the Surveillance of Potential Harms Caused by Food Supplements in Europe
14. Withdrawal Syndrome Following Discontinuation of 28 Antidepressants: Pharmacovigilance Analysis of 31,688 Reports from the WHO Spontaneous Reporting Database
15. Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) Database
16. Authors’ Reply to Cappello et al. Comment on: “Deliberate Self-Poisoning: Real-Time Characterization of Suicidal Habits and Toxidromes in the Food and Drug Administration Adverse Event Reporting System”
17. Amyotrophic Lateral Sclerosis as an Adverse Drug Reaction: A Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System
18. Crystal nephropathy and amoxicillin: insights from international spontaneous reporting systems
19. Skin Toxicities with Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Signals from Disproportionality Analysis of the FDA Adverse Event Reporting System
20. Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System
21. Liver Injury with Ulipristal Acetate: Exploring the Underlying Pharmacological Basis
22. Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilance
23. Drug–Drug Interactions between Direct Oral Anticoagulants and Hepatitis C Direct-Acting Antiviral Agents: Looking for Evidence Through a Systematic Review
24. Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance
25. DPP-4 Inhibitors in Combination with Lipid-Lowering Agents and Risk of Serious Muscular Injury: A Nested Case-Control Study in a Nationwide Cohort of Patients with Type 2 Diabetes Mellitus
26. Comparative Effectiveness and Safety of Direct Oral Anticoagulants: Overview of Systematic Reviews
27. Authors’ Reply to Robert P. Giugliano and Colleagues’ Comment on: “Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilance”
28. Balancing the Need for Personalization of QT Correction and Generalization of Study Results: Going Beyond Thorough QT Studies
29. ESC position paper on cardiovascular toxicity of cancer treatments: challenges and expectations
30. Occurrence of Multiple Sclerosis After Drug Exposure: Insights From Evidence Mapping
31. Evolving cardiovascular uses of direct-acting oral anticoagulants: a paradigm shift on the horizon?
32. Drug-Induced Arrhythmia: Bridging the Gap Between Pathophysiological Knowledge and Clinical Practice
33. Risk–Benefit Profile of Direct-Acting Oral Anticoagulants in Established Therapeutic Indications: An Overview of Systematic Reviews and Observational Studies
34. The Contribution of National Spontaneous Reporting Systems to Detect Signals of Torsadogenicity: Issues Emerging from the ARITMO Project
35. Drug-Induced Renal Damage in Preterm Neonates: State of the Art and Methods for Early Detection
36. ESC position paper on cardiovascular toxicity of cancer treatments: challenges and expectations—authors’ reply
37. Cardiovascular, Ocular and Bone Adverse Reactions Associated with Thiazolidinediones: A Disproportionality Analysis of the US FDA Adverse Event Reporting System Database
38. Antimicrobials and the Risk of Torsades de Pointes: The Contribution from Data Mining of the US FDA Adverse Event Reporting System
39. Structure and composition of a Mediterranean grassland community grown under Free-Air CO2 Enrichment (MiniFACE)
40. Soil respiration and microbial activity in a Mediterranean grassland exposed to Free Air CO2 Enrichment (FACE)
41. Authors’ Reply to Alain Braillon’s Comment on “The Contribution of National Spontaneous Reporting Systems to Detect Signals of Torsadogenicity: Issues Emerging from the ARITMO Project”
42. Photosynthetic Responses of Forest-Floor Moss Species to Elevated CO2 Level by a Natural CO2 Vents
43. Comment on: “Pharmacokinetics in Patients with Chronic Liver Disease and Hepatic Safety of Incretin-Based Therapies for the Management of Type 2 Diabetes Mellitus”
44. Drug-Induced Renal Damage in Preterm Neonates: State of the Art and Methods for Early Detection
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.